Antonio Pisani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7296337/publications.pdf

Version: 2024-02-01

181	6,940	66343	71685
papers	citations	42 h-index	76 g-index

183	183	183	7651
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?. Journal of Nuclear Cardiology, 2022, 29, 1439-1445.	2.1	3
2	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. Heart Failure Clinics, 2022, 18, 39-49.	2.1	18
3	The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease. European Radiology, 2022, , 1.	4.5	4
4	RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study. Frontiers in Cardiovascular Medicine, 2022, 9, 824095.	2.4	9
5	New insights for early assessment of cardiac involvement in Anderson-Fabry disease. Journal of Nuclear Cardiology, 2021, 28, 2500-2502.	2.1	1
6	Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease. Journal of Nuclear Cardiology, 2021, 28, 641-649.	2.1	6
7	Does left ventricular function predict cardiac outcome in Andersonâ€“Fabry disease?. International Journal of Cardiovascular Imaging, 2021, 37, 1225-1236.	1.5	13
8	Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells. Toxicology Reports, 2021, 8, 816-821.	3.3	1
9	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. CKJ: Clinical Kidney Journal, 2021, 14, 1488-1490.	2.9	3
10	DNA methylation impact on Fabry disease. Clinical Epigenetics, 2021, 13, 24.	4.1	16
11	Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia. Brain, 2021, 144, 909-923.	7.6	22
12	Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol. Molecular Genetics & Genomic Medicine, 2021, 9, e1659.	1.2	4
13	Nonvascular Parkinsonism in Fabry Disease: Results From Magnetic Resonance and Dopamine Transporter Imaging. Journal of Neuropathology and Experimental Neurology, 2021, 80, 476-479.	1.7	2
14	Therapeutic advances in ADPKD: the future awaits. Journal of Nephrology, 2021, , 1.	2.0	20
15	Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in <scp>DYT1</scp> Dystonia. Movement Disorders, 2021, 36, 2768-2779.	3.9	10
16	The Role of Immunosuppressive Therapy in Aneurysmal Degeneration of Hemodialysis Fistulas in Renal Transplant Patients. Annals of Vascular Surgery, 2021, 74, 21-28.	0.9	3
17	Role of serial cardiac 18F-FDG PET-MRI in Andersonâ€“Fabry disease: a pilot study. Insights Into Imaging, 2021, 12, 124.	3.4	7
18	Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: â€œCan the Promise Be Kept?â€• International Journal of Molecular Sciences, 2021, 22, 12590.	4.1	7

#	Article	IF	Citations
19	The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials. Scientific Reports, 2021, 11, 23500.	3.3	8
20	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Andersonâ€“Fabry disease. Cell Death and Disease, 2021, 12, 1150.	6.3	6
21	MALDI imaging in Fabry nephropathy: a multicenter study. Journal of Nephrology, 2020, 33, 299-306.	2.0	5
22	Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. Molecular Genetics and Metabolism, 2020, 129, 132-141.	1.1	25
23	Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995â€“2019. Journal of Nephrology, 2020, 33, 569-581.	2.0	17
24	Early Predictors of Arteriovenous Fistula Maturation: Preoperative Arterial Diameter Alone Is Not Enough. Journal of the American Society of Nephrology: JASN, 2020, 31, 2226-2228.	6.1	1
25	Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. European Journal of Human Genetics, 2020, 28, 1662-1668.	2.8	37
26	Predictive effect of salt intake on patient and kidney survival in non-dialysis CKD: competing risk analysis in older versus younger patients under nephrology care. Nephrology Dialysis Transplantation, 2020, 36, 2232-2240.	0.7	7
27	Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study. Neuroradiology, 2020, 62, 1459-1466.	2.2	7
28	Impact of COVID-19 pandemic on patients with Fabry disease: An Italian experience. Molecular Genetics and Metabolism, 2020, 131, 124-125.	1.1	11
29	Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis. Journal of Clinical Medicine, 2020, 9, 2741.	2.4	6
30	The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study. Journal of Clinical Medicine, 2020, 9, 4087.	2.4	9
31	Renal Denervation for Resistant Hypertension: Time to Improve Patient Selection. The Lesson From ADPKD. Frontiers in Medicine, 2020, 7, 604384.	2.6	0
32	Acute Kidney Injury in COVID-19 Pandemic. Nephron, 2020, 144, 345-346.	1.8	6
33	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. PLoS ONE, 2020, 15, e0233050.	2.5	13
34	COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?. Nephron, 2020, 144, 383-385.	1.8	6
35	Oral SucrosomialÂ® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. BMC Nephrology, 2020, 21, 57.	1.8	12
36	Left ventricular radial strain impairment precedes hypertrophy in Andersonâ€“Fabry disease. International Journal of Cardiovascular Imaging, 2020, 36, 1465-1476.	1.5	5

#	Article	IF	Citations
37	Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study. Journal of the Neurological Sciences, 2020, 412, 116782.	0.6	2
38	The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts. Orphanet Journal of Rare Diseases, 2020, 15, 86.	2.7	9
39	Title is missing!. , 2020, 15, e0233050.		0
40	Title is missing!. , 2020, 15, e0233050.		0
41	Title is missing!. , 2020, 15, e0233050.		0
42	Title is missing!. , 2020, 15, e0233050.		0
43	Title is missing!. , 2020, 15, e0233050.		0
44	Title is missing!. , 2020, 15, e0233050.		0
45	Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naÃ¯ve Anderson-Fabry disease patients. European Heart Journal Cardiovascular Imaging, 2019, 20, 438-445.	1.2	34
46	Dystonia and dopamine: From phenomenology to pathophysiology. Progress in Neurobiology, 2019, 182, 101678.	5.7	53
47	ADPKD and metformin: from bench to bedside. Clinical and Experimental Nephrology, 2019, 23, 1341-1342.	1.6	7
48	Layerâ€specific longitudinal strain in Andersonâ€“Fabry diseaseÂat diagnosis: A speckle tracking echocardiography analysis. Echocardiography, 2019, 36, 1273-1281.	0.9	13
49	Early Biomarkers of Fabry Nephropathy: A Review of the Literature. Nephron, 2019, 143, 274-281.	1.8	19
50	Optical Coherence Tomography Angiography Findings in Fabry Disease. Journal of Clinical Medicine, 2019, 8, 528.	2.4	21
51	Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Andersonâ€“Fabry disease: AFFINITY study group. European Heart Journal Cardiovascular Imaging, 2019, 20, 1004-1011.	1.2	28
52	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	8.4	42
53	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 1177-1190.	4.4	14
54	Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. BMC Nephrology, 2019, 20, 426.	1.8	8

#	Article	IF	Citations
55	New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases. CKJ: Clinical Kidney Journal, 2019, 12, 65-70.	2.9	10
56	Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease. Nephron, 2019, 141, 10-17.	1.8	18
57	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. International Journal of Cardiology, 2019, 275, 145-151.	1.7	13
58	Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying Î±-Galactosidase A Mutation. Circulation: Cardiovascular Imaging, 2018, 11, e007019.	2.6	31
59	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. Journal of Neural Transmission, 2018, 125, 673-679.	2.8	31
60	Motor involvement in Fabry disease. Molecular Genetics and Metabolism Reports, 2018, 14, 43.	1.1	4
61	Default mode network modifications in <scp>F</scp>abry disease: A restingâ€state fMRI study with structural correlations. Human Brain Mapping, 2018, 39, 1755-1764.	3.6	25
62	Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrology Dialysis Transplantation, 2018, 33, 318-323.	0.7	21
63	Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells. Journal of Cellular Physiology, 2018, 233, 4116-4125.	4.1	16
64	Enhanced mu opioid receptorâ€“dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. Movement Disorders, 2018, 33, 310-320.	3.9	20
65	Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clinical and Experimental Nephrology, 2018, 22, 529-538.	1.6	18
66	An unusual case of tuberous sclerosis incidentally discovered in adulthood: case report and review of the literature. Acta Radiologica Open, 2018, 7, 205846011880632.	0.6	1
67	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. Data in Brief, 2018, 21, 2075-2081.	1.0	5
68	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. International Journal of Molecular Sciences, 2018, 19, 3726.	4.1	63
69	Neuroimaging in Fabry disease: current knowledge and future directions. Insights Into Imaging, 2018, 9, 1077-1088.	3.4	37
70	Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family. Multiple Sclerosis and Related Disorders, 2018, 26, 164-167.	2.0	4
71	Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis. Brain and Behavior, 2018, 8, e01121.	2.2	13
72	Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?. BMC Nephrology, 2018, 19, 282.	1.8	24

#	Article	IF	Citations
73	Reduced Intracranial Volume in Fabry Disease: Evidence of Abnormal Neurodevelopment?. Frontiers in Neurology, 2018, 9, 672.	2.4	12
74	Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study. Parkinsonism and Related Disorders, 2018, 57, 27-32.	2.2	10
75	A pilot study of circulating microRNAs as potential biomarkers of Fabry disease. Oncotarget, 2018, 9, 27333-27345.	1.8	20
76	Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease. Journal of Cardiovascular Echography, 2018, 28, 120.	0.4	10
77	Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. Neuroradiology, 2017, 59, 563-570.	2.2	30
78	Alterations of functional connectivity of the motor cortex in Fabry disease. Neurology, 2017, 88, 1822-1829.	1.1	19
79	The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. European Journal of Internal Medicine, 2017, 39, 1-8.	2.2	85
80	Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study. Neurology, 2017, 89, 1842-1843.	1.1	0
81	Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. Journal of the American College of Nutrition, 2017, 36, 586-591.	1.8	21
82	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Internal and Emergency Medicine, 2017, 12, 1059-1067.	2.0	7
83	Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2266-2273.	6.4	31
84	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. Future Cardiology, 2017, 13, 521-527.	1.2	2
85	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. Aging Clinical and Experimental Research, 2017, 29, 73-78.	2.9	19
86	Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. Genetics in Medicine, 2017, 19, 275-282.	2.4	11
87	Parapelvic Cysts: A Suspicious Feature of Fabry Disease. Giornale De Techniche Nefrologiche & Dialitiche, 2017, 29, 101-102.	0.1	0
88	Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. BioMed Research International, 2017, 2017, 1-8.	1.9	32
89	Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. BioMed Research International, 2017, 2017, 1-11.	1.9	75
90	Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. Oncotarget, 2017, 8, 107558-107564.	1.8	30

#	Article	IF	Citations
91	The potential use of biomarkers in predicting contrast-induced acute kidney injury. International Journal of Nephrology and Renovascular Disease, 2016, Volume 9, 205-221.	1.8	45
92	Hyperkinetic disorders and loss of synaptic downscaling. Nature Neuroscience, 2016, 19, 868-875.	14.8	98
93	Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Journal of Nephrology, 2016, 29, 71-78.	2.0	22
94	What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. International Journal of Surgery, 2016, 28, S172-S176.	2.7	20
95	Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 729-739.	6.4	13
96	Long-term Effects of Octreotide on Liver Volume in Patients WithÂPolycystic Kidney and Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1022-1030.e4.	4.4	45
97	Molecular and clinical studies in five index cases with novel mutations in the GLA gene. Gene, 2016, 578, 100-104.	2.2	20
98	6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial. Clinical and Experimental Nephrology, 2016, 20, 433-442.	1.6	27
99	Genetic variants associated with gastrointestinal symptoms in Fabry disease. Oncotarget, 2016, 7, 85895-85904.	1.8	30
100	Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. BMC Research Notes, 2015, 8, 711.	1.4	9
101	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. Frontiers in Neurology, 2015, 6, 86.	2.4	39
102	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. BioMed Research International, 2015, 2015, 1-8.	1.9	20
103	Pituitary function and morphology in Fabry disease. Endocrine, 2015, 50, 483-488.	2.3	5
104	Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract. Chemico-Biological Interactions, 2015, 229, 17-25.	4.0	21
105	Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. Nephrology Dialysis Transplantation, 2015, 30, 661-666.	0.7	19
106	Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?. Genetics in Medicine, 2015, 17, 21-23.	2.4	5
107	Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial. PLoS ONE, 2015, 10, e0118174.	2.5	30
108	Atrial septum aneurysm: an unusual manifestation in ADPKD?. Clinical and Experimental Nephrology, 2015, 19, 1206-1207.	1.6	0

#	Article	IF	Citations
109	Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. Neurobiology of Disease, 2015, 78, 146-161.	4.4	25
110	First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1025-1031.	6.4	71
111	Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation, 2015, 30, 645-652.	0.7	113
112	Nutritional treatment in chronic kidney disease: the concept of nephroprotection. Clinical and Experimental Nephrology, 2015, 19, 161-167.	1.6	18
113	Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors. Scientific World Journal, The, 2014, 2014, 1-16.	2.1	86
114	The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy. Advances in Nephrology, 2014, 2014, 1-11.	0.2	10
115	Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M₁ muscarinic receptors. Movement Disorders, 2014, 29, 1655-1665.	3.9	152
116	Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Preference and Adherence, 2014, 8, 73.	1.8	33
117	Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention. BioMed Research International, 2014, 2014, 1-21.	1.9	95
118	Endothelial-mediated coronary flow reserve in patients with Andersonâ€“Fabry disease. International Journal of Cardiology, 2014, 177, 1059-1060.	1.7	1
119	Catheter-Based Renal Denervation in ADPKD: Just for Pain Control?. American Journal of Kidney Diseases, 2014, 64, 999.	1.9	3
120	Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media. BioMed Research International, 2014, 2014, 1-10.	1.9	32
121	Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease. Journal of Inherited Metabolic Disease, 2014, 37, 145-146.	3.6	5
122	Renal Sympatheticâ€Nerve Ablation for Uncontrolled Hypertension in a Patient With Singleâ€Kidney Autosomal Dominant Polycystic Kidney Disease. Journal of Clinical Hypertension, 2014, 16, 385-386.	2.0	11
123	Fanconi syndrome with lysinuric protein intolerance. CKJ: Clinical Kidney Journal, 2014, 7, 599-601.	2.9	13
124	Arterial aneurysms: autosomal dominant polycystic kidney disease, Marfan syndrome or both?. Clinical and Experimental Nephrology, 2014, 18, 672-673.	1.6	1
125	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2014, 25, 850-863.	6.1	199
126	Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. American Journal of Physiology - Renal Physiology, 2014, 306, F1243-F1250.	2.7	16

#	Article	IF	Citations
127	Differential Activation of Signaling Pathways by Lowâ€Osmolar and Isoâ€Osmolar Radiocontrast Agents in Human Renal Tubular Cells. Journal of Cellular Biochemistry, 2014, 115, 281-289.	2.6	33
128	Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clinical and Experimental Nephrology, 2013, 18, 424-31.	1.6	46
129	Pleural effusion in peritoneal dialysis: overload or leakage?. Clinical and Experimental Nephrology, 2013, 17, 907-907.	1.6	3
130	Polycystic horseshoe kidney. Clinical and Experimental Nephrology, 2013, 17, 905-906.	1.6	1
131	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	13.7	218
132	Role of Reactive Oxygen Species in Pathogenesis of Radiocontrast-Induced Nephropathy. BioMed Research International, 2013, 2013, 1-6.	1.9	82
133	Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 Dystonia. Journal of Neuroscience, 2012, 32, 11991-12004.	3.6	93
134	Nephrotic syndrome and autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2012, 5, 508-511.	2.9	9
135	Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation, 2012, 27, 3560-3567.	0.7	49
136	Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature. Molecular Genetics and Metabolism, 2012, 107, 267-275.	1.1	87
137	A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovascular Disorders, 2012, 12, 39.	1.7	16
138	Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinsonâ€™s disease. Journal of Neuroinflammation, 2012, 9, 188.	7.2	115
139	How relevant is the cholinergic system in DYT1 dystonia?. Basal Ganglia, 2012, 2, 227-230.	0.3	0
140	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. PLoS ONE, 2012, 7, e32533.	2.5	46
141	Synergy between the pharmacological chaperone 1â€deoxygalactonojirimycin and the human recombinant alphaâ€galactosidase A in cultured fibroblasts from patients with Fabry disease. Journal of Inherited Metabolic Disease, 2012, 35, 513-520.	3.6	40
142	A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency. Journal of Nephrology, 2012, 25, 582-585.	2.0	2
143	Abnormal plasticity in dystonia: Disruption of synaptic homeostasis. Neurobiology of Disease, 2011, 42, 162-170.	4.4	144
144	Towards a new era for dystonia, a high priority for biomedical research. Neurobiology of Disease, 2011, 42, 125-126.	4.4	5

#	Article	IF	Citations
145	Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function. Frontiers in Neuroanatomy, 2011, 5, 6.	1.7	113
146	Experimental Models of Dystonia. International Review of Neurobiology, 2011, 98, 551-572.	2.0	15
147	Clinical treatment of polycystic kidney disease (APKD): do we need further suggestions from rodents?. Nephrology Dialysis Transplantation, 2011, 26, 2065-2066.	0.7	3
148	Differential Activation of Signaling Pathways Involved in Cell Death, Survival and Inflammation by Radiocontrast Media in Human Renal Proximal Tubular Cells. Toxicological Sciences, 2011, 119, 408-416.	3.1	42
149	Developmental Profile of the Aberrant Dopamine D2 Receptor Response in Striatal Cholinergic Interneurons in DYT1 Dystonia. PLoS ONE, 2011, 6, e24261.	2.5	77
150	Simultaneous multicystic kidney and Anderson-Fabry disease: 2 separate entities or same side of the coin. Journal of Nephrology, 2011, 24, 806-808.	2.0	9
151	Mycophenolic acid inhibits the phosphorylation of NF-Î¹B and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chemico-Biological Interactions, 2010, 185, 253-262.	4.0	35
152	Effects of mycophenolate mofetil on acute ischaemia-reperfusion injury in rats and its consequences in the long term. Nephrology Dialysis Transplantation, 2010, 25, 1443-1450.	0.7	10
153	Electrophysiology of 5-HT6 Receptors. International Review of Neurobiology, 2010, 94, 111-128.	2.0	10
154	Setting dialysis start at 6.0 ml/min/1.73 m2 eGFR--a study on safety, quality of life and economic impact. Nephrology Dialysis Transplantation, 2009, 24, 3434-3440.	0.7	26
155	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain, 2009, 132, 2336-2349.	7.6	197
156	Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiology of Disease, 2009, 34, 133-145.	4.4	80
157	Effect of a Low- Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. American Journal of Kidney Diseases, 2009, 54, 1052-1061.	1.9	64
158	ECâ€MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMFâ€related gastrointestinal sideâ€effects. Fundamental and Clinical Pharmacology, 2009, 23, 617-624.	1.9	30
159	Cholinergic Interneuron and Parkinsonism. , 2009, , 1-11.		0
160	Sleep quality in patients with chronic renal failure: A 3-year longitudinal study. Sleep Medicine, 2008, 9, 240-246.	1.6	47
161	Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrology Dialysis Transplantation, 2008, 23, 1628-1635.	0.7	44
162	Loss of Muscarinic Autoreceptor Function Impairs Long-Term Depression But Not Long-Term Potentiation in the Striatum. Journal of Neuroscience, 2008, 28, 6258-6263.	3.6	81

#	Article	IF	Citations
163	Endogenous Serotonin Excites Striatal Cholinergic Interneurons via the Activation of 5-HT 2C, 5-HT6, and 5-HT7 Serotonin Receptors: Implications for Extrapyramidal Side Effects of Serotonin Reuptake Inhibitors. Neuropsychopharmacology, 2007, 32, 1840-1854.	5.4	122
164	MRI Characterization of Myocardial Tissue in Patients with Fabry's Disease. American Journal of Roentgenology, 2007, 188, 850-853.	2.2	36
165	Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. Nephrology Dialysis Transplantation, 2007, 23, 636-644.	0.7	93
166	Re-emergence of striatal cholinergic interneurons in movement disorders. Trends in Neurosciences, 2007, 30, 545-553.	8.6	400
167	Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. American Journal of Physiology - Renal Physiology, 2006, 290, F1408-F1415.	2.7	46
168	Enzyme Replacement Therapy in Fabry Disease Patients Undergoing Dialysis: Effects on Quality of Life and Organ Involvement. American Journal of Kidney Diseases, 2005, 46, 120-127.	1.9	63
169	Sleep quality in renal transplant patients: a never investigated problem. Nephrology Dialysis Transplantation, 2005, 20, 194-198.	0.7	80
170	Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. Learning and Memory, 2004, 11, 755-760.	1.3	23
171	Atorvastatin Improves the Course of Ischemic Acute Renal Failure in Aging Rats. Journal of the American Society of Nephrology: JASN, 2004, 15, 901-909.	6.1	68
172	Zaleplon Improves Sleep Quality in Maintenance Hemodialysis Patients. Nephron Clinical Practice, 2003, 94, c99-c103.	2.3	30
173	The impact of haemoglobin on the quality of sleep in haemodialysis patients: which is the truth?. Nephrology Dialysis Transplantation, 2003, 18, 1947-1948.	0.7	7
174	Arginase inhibition slows the progression of renal failure in rats with renal ablation. American Journal of Physiology - Renal Physiology, 2003, 284, F680-F687.	2.7	25
175	Insomnia in maintenance haemodialysis patients. Nephrology Dialysis Transplantation, 2002, 17, 852-856.	0.7	154
176	Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. American Journal of Kidney Diseases, 2001, 38, 18-25.	1.9	242
177	Activation of D2-Like Dopamine Receptors Reduces Synaptic Inputs to Striatal Cholinergic Interneurons. Journal of Neuroscience, 2000, 20, RC69-RC69.	3.6	144
178	Acetylcholine-mediated modulation of striatal function. Trends in Neurosciences, 2000, 23, 120-126.	8.6	400
179	Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. American Journal of Kidney Diseases, 1999, 33, 851-856.	1.9	228
180	Muscarinic IPSPs in rat striatal cholinergic interneurones. Journal of Physiology, 1998, 510, 421-427.	2.9	83

#	Article	IF	Citations
181	Animal Models of Dystonia. , 0, , 49-52.		0